Company intelligence / Profile preview
Maze Therapeutics
South San Francisco, California, United Statesir.mazetx.com ↗
- Ownership
- Public · MAZE
- Employees
- ~125
- Development stage
- Phase 2
01
Overview
Maze Therapeutics has two main clinical-stage programs targeting chronic kidney disease. MZE829, an oral small molecule inhibitor of APOL1, is in a phase II trial for APOL1 kidney disease. MZE782, an oral small molecule inhibitor of SLC6A19, is in phase I trials with initial data expected in the second half of 2025. The company also has a program for Pompe disease and leverages its proprietary Compass platform to drive precision medicine development based on human genetics.[2][3] No pivotal or late-stage results have been reported as of May 2025.
- Therapeutic areas
- Rare DiseasesCardiovascularMetabolic DisordersNephrology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $1.5B
- Total revenue
- $0
- Enterprise value
- $1.1B
Beyond the preview
Go deeper on Maze Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Maze Therapeutics.